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4 min after the onset of symptoms may be helpful to diag-
nose food allergy. Because of numerous confounding vari-
ables, however, a negative saliva MCT increase does not ex-
clude food allergy.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Systemic allergic reactions or local oral symptoms 
(oral allergy syndrome; OAS) are manifestations of food 
allergy. Characteristic symptoms of OAS are itching and/
or swelling of the oropharyngeal mucosa immediately 
after contact with food allergens. In many cases, these 
unpleasant symptoms prevent the patient from further 
consuming the food allergen. This type of behavior lim-
its the individual’s allergen exposure and may explain 
why many patients have only oral, but no systemic symp-
toms to food allergens. Another reason for the low inci-
dence of systemic reactions in patients with OAS might 
result from the instability of some food allergens, which 
are degraded rapidly by oxidation or by digestive secre-
tions. However, some patients with OAS may develop 
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 Abstract 
 Background: Our aim was to examine whether measure-
ment of the saliva mast cell tryptase (MCT) concentrations 
before and after a mucosal challenge test with the offending 
food would be helpful in diagnosing food allergy.  Methods: 
We performed a retrospective analysis of 44 food challenge 
tests performed in 38 patients between 2006 and 2009. Pa-
tients with a suspected history of food allergy chewed the 
food until they developed symptoms or until the amount of 
time known from the patients’ history to usually be required 
for the provocation of symptoms had passed. In 5 patients, 
saliva samples for the measurement of MCT were collected 
at minutes 0, 1, 4, 8, 11, and 16 after the first onset of symp-
toms. The remainder of the patients only had samples taken 
before chewing and 4 min after the end of the test period. 
 Results: During repeated measurements, MCT peaked about 
4 min after the onset of symptoms (p = 0.028). During 33 of 
the 44 tests (75.0%), we observed oral symptoms during test-
ing; after 25 of the 33 (75.8%) tests evoking symptoms, the 
saliva MCT concentration increased. The MCT increase was 
negative in all other tests where no oral symptoms could
be provoked.  Conclusions: The measurement of saliva MCT 
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systemic symptoms up to the point of anaphylactic shock 
 [1–3] . 
 In patients with systemic allergic reactions after food 
exposure, a double-blind placebo-controlled food chal-
lenge (DBPCFC), which includes swallowing the culprit 
food, is the diagnostic procedure of choice. The standard 
procedure to diagnose OAS is mainly based on a history 
of typical local symptoms shortly after exposure to cer-
tain foods. Results of skin prick tests and/or of measure-
ments of specific serum IgE antibodies may be also help-
ful but are affected by a comparably low accuracy. The use 
of mucosal challenge tests is limited because they require 
specific local symptoms which, however, are rarely un-
equivocal. To date, an objective parameter to verify oral 
symptoms is not available.
 An increase in the mast cell tryptase (MCT) concen-
tration in bodily fluids is a diagnostic correlate of mast 
cell-related events and was found for the first time in the 
serum of patients with anaphylactic reactions  [4, 5] . After 
a local allergen challenge, MCT concentrations also rise 
in nasal secretions  [6–8] , tears  [9] , bronchoalveolar lavage 
fluid  [10] , and sputum  [7] . 
 A preliminary study in patients with food allergy sug-
gested that measurement of the saliva MCT concentra-
tions before and after an oral food challenge may not be 
a suitable tool to document local reactivity  [11] . The ex-
perimental design of the latter study, however, may have 
been inadequate. Since 2006, we have been using a mod-
ified routine procedure for oral food challenges and the 
measurement of saliva MCT concentrations. These dif-
ferences mainly concern the food exposure time and the 
time when MCT is measured after the challenge. Before 
establishing a fixed time point for MCT measurement, we 
examined the postchallenge kinetics of saliva MCT in pa-
tients with OAS. We performed mucosal food challenges 
in patients with a history of OAS, but also in patients who 
exclusively developed systemic allergic reactions after 
food ingestion. In the latter patients, we also tried to avoid 
DBPCFC and the risk of a subsequent severe anaphylactic 
reaction. In the present communication, we report our 
preliminary experience with this modified challenge 
procedure in diagnosing food allergy.
 Methods 
 Subjects 
 We conducted a retrospective search for all patients who had 
presented with a history of food allergy in our outpatient clinic 
and who had undergone a routine food challenge test including 
postchallenge saliva MCT measurements between 2006 and 2009. 
Patients who had received antihistamines or other drugs with an 
antihistamine-like action (e.g. antidepressants) were not consid-
ered for the evaluation. Patients who had not been sensitized to 
the suspected food were also excluded from the evaluation. 
 The retrospective analysis of anonymous data was approved 
by the local institutional review board.
 Basic Allergy Diagnostics 
 The patients’ history included atopic diseases, the type of 
symptoms induced by foods, offending foods, the perceived elicit-
ing dose of the respective food, the time interval between food 
intake and the onset of systemic or local symptoms, and medica-
tions used. Skin prick tests were performed using a standard series 
(ALK-Abelló, Hørsholm, Denmark; Allergopharma Joachim 
Ganzer KG, Reinbek, Germany; Bencard Allergie GmbH, Mu-
nich, Germany; HAL Allergy, Leiden, The Netherlands, or Stal-
lergenes, Antony Cedex, France) which included the suspected 
foods. If there was no prick test reaction to a commercial test so-
lution of the suspected food, fresh foods were used. A positive skin 
prick test was defined as a wheal of  6 3 mm in diameter. Physio-
logic saline served as a negative control, and histamine dihydro-
chloride (10 mg/ml) served as a positive control. Specific serum 
IgE antibodies to the suspected food were measured by Immuno-
CAP (Phadia, Freiburg, Germany).
 Mucosal Challenge Test and Measurement of MCT in Saliva 
 The tests were performed with fresh foods, which were poten-
tial candidates for an allergic reaction according to history and 
test results. The routine test procedures were standardized. Before 
testing, written consent was obtained from all patients or legal 
guardians. The average amount of test food corresponded to that 
consumed by a usual bite – about 3–10 g. Patients took this amount 
of food into their mouth and started to chew in the customary 
manner until they developed symptoms or until the amount of 
time had passed which was known from the same patients’ his-
tory to usually be required for the provocation of oral symptoms. 
Patients without a history of oral reactions also started to chew 
until they developed symptoms or until the amount of time which 
was known from other patients’ history to usually be required for 
the provocation of symptoms had passed. If the food had already 
been thoroughly chewed before the end of this time span was 
reached, the patient spat out the previous test dose and took an-
other equal dose of fresh food into his or her mouth. The patients 
were advised to avoid any swallowing of the food. 
 If symptoms of any kind occurred during the test period, the 
test was considered clinically positive and was immediately 
stopped by properly spitting out the food, if necessary, several 
times. Patients were not allowed to rinse their mouth or to brush 
their teeth after the end of the test. The test was considered clini-
cally negative if no symptoms occurred until the end of the test 
period. Saliva samples were obtained using the cotton wool meth-
od  [12] as follows: Small absorbent cotton wool dental rolls (Cel-
luron Zahnwatterollen; Hartmann, Heidenheim, Germany) with 
a length of about 4 cm and a diameter of about 6 mm were placed 
under the tongue. Each sampling period lasted 1 min. After their 
removal, the dental rolls were centrifuged (3,000 rpm, 10 min, 
4  °  C), and the supernatants were analyzed for MCT by Immuno-
CAP (Phadia). The detection limit of MCT was 1   g/l. An in-
crease in saliva MCT from baseline of more than 20% was defined 
as a positive test result. 
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 In the first 5 patients with a high likelihood of suffering from 
OAS (6 challenge tests), saliva samples were collected at various 
points in time, i.e. before (0 min), immediately (1 min), and 4, 8, 
11, and 16 min after the onset of symptoms. In subsequent pa-
tients, saliva MCT was only measured before the test and 4 min 
after the first symptoms had occurred. In case of a negative clini-
cal result, corresponding measurements were taken 4 min after 
the end of the test period. In a few selected patients with a positive 
clinical response and a saliva MCT increase, placebo challenges 
(chewing gum) were done to exclude unspecific effects.
 Control Challenge Tests in Healthy Volunteers  
 Three healthy controls (1 male, 30 years old, and 2 females, 30 
and 51 years old, respectively) were studied to exclude an unspe-
cific oral MCT release by the act of mastication. The subjects 
chewed up to 90 g of carrots for 3 min. Controls were matched ac-
cording to age and food exposure time. A 3-min test time was 
used in controls because this was the average amount of exposure 
time, which was known from the patient’s history to usually be 
required for the provocation of symptoms. The type of food was 
not matched with the food tested in the patients. Instead, we want-
ed to test in controls the type of food which would lead to the 
greatest physical strain during the act of mastication. 
 Statistics 
 Data were analyzed using software (SPSS 15.0; SPSS, Inc., Chi-
cago, Ill., USA). Values are given as medians and ranges or means. 
Wilcoxon’s test was used to compare different means of saliva 
MCT levels.   2 tests were used to compare categorical variables.
p  ! 0.05 was considered statistically significant.
 Results 
 Clinical Observations 
 Altogether, 38 patients (9 males and 29 females, me-
dian age 34.5 years, range 10–71) with a history of food 
allergy and sensitization to the suspected food, in whom 
we had performed mucosal tests with 44 foods, were iden-
tified. Thirty-three of these patients had a history of atop-
ic diseases [allergic rhinoconjunctivitis (n = 31); asthma 
(n = 10), and atopic eczema (n = 6)]. Thirty-one patients 
had a history of OAS; another 7 patients were tested to 
diagnose a food allergy with a history of an exclusively 
systemic allergic response after food intake.
 During 44 challenges 33 oral reactions (75.0%) oc-
curred, none of which was associated with a subsequent 
systemic allergic reaction. Oral symptoms cleared within 
2–15 min after the end of the test. Mild symptoms faded 
sooner than more intensive symptoms. Details are given 
in  table 1 . On average, the median exposure time to the 
development of clinical symptoms during a challenge test 
was 135 s (range 40–510). The median amount of chewed 
food was 11.7 g (range 0.02–79). In 11 challenge tests, we 
could not provoke oral allergic reactions. For those tests, 
the median exposure time was 1 min (range 1–10), and the 
median amount of food chewed was 22.3 g (range 5.7–
164.3). After one of the challenge tests, during which we 
did not observe an oral reaction, a systemic reaction oc-
curred after the end of the test. This patient was a 35-year-
old male with a suspected sesame allergy. Upon mucosal 
challenge with 11.6 g sesame, he suffered from urticaria, 
dizziness, and dyspnoea 15 min after the test. Placebo 
challenges in 3 patients and dummy challenges in 3 con-
trol subjects were not associated with any oral reactions.
 Kinetics of MCT Release into Saliva 
 Six kinetic analyses were performed in 5 subjects. Re-
peated measurements were performed with 1 food in 4 
patients and with 2 different foods in 1 patient (patient 
No. 3). In the majority of the tests, saliva MCT concentra-
tions were already increased 4 min after the appearance 
of the first symptoms. However, the time of the maxi-
mum concentration was not uniform. In patient No. 9 
(test with 7.6 g apple) the saliva MCT concentration rose 
for the first time only 16 min after the beginning of the 
symptoms ( fig. 1 ). This patient was challenged a second 
time with an artificially higher dose of apple (48.3 g), 
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 Fig. 1. Kinetics of the saliva MCT concentration after food expo-
sure. Six tests were performed in 5 patients with a high likelihood 
of suffering from an OAS. Saliva samples were collected before
(0 min), immediately (1 min), and 4, 8, 11, and 16 min after the 
onset of oral symptoms. Patient numbers are given in parenthe-
ses. 
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causing an accelerated MCT release already detectable 4 
min after the onset of symptoms. On average, the maxi-
mum MCT during follow-up were significantly higher 
than the basal values (mean 13.1  8 21.4   g/l, median 5.2 
  g/l, range 1.64–56.6, vs. mean 0.24  8 0.58   g/l, medi-
an 0   g/l, range  ! 1.0–1.42; p = 0.028).
 Postchallenge Saliva MCT Concentration  
 On the basis of the results of the kinetic analyses, and 
for the sake of simplicity, we decided to subsequently 
measure saliva MCT concentrations only 4 min after the 
beginning of the symptoms or after the end of the test 
period. In 3 of the 30 patients with oral symptoms and in 
1 of 8 patients without symptoms at the challenge test, 
MCT was demonstrable in saliva at baseline ( table 2 ). Al-
together, in 23 patients, food challenge caused an eleva-
tion in saliva MCT 4 min after the beginning of the first 
symptoms in 25 tests versus baseline (median 2.7   g/l, 
range 0–79.4, mean 9.1  8 17.1   g/l, vs. median 0, range 
0–2.6, mean 0.2  8 0.6   g/l; p = 0.001) ( table 2 ). The sa-
Table 1.  Patient and test characteristics (patients No. 3, 15, and 23 were tested twice with different foods)
Patient
No.
Age
years
Sex Tested food Types of previous
symptoms 
Food-specific IgE
concentration, kU/l 
Prick test reaction
to tested food
History of
atopic diseases
1 36 F kiwi OAS 1.64 yes no
2 54 F almond OAS, AX III 9.79 yes RCA
3a 21 F hazelnut OAS 3.65 yes A, RCA
3b almond OAS <0.35 yes
4 20 F peach OAS 0.47 yes AE
5 29 M hazelnut OAS 1.48 yes RCA
6 35 F carrot OAS 3.78 n.d. RCA
7 60 F soy drink OAS <0.35 yes A, RCA
8 24 F carrot OAS 3.47 yes A, RCA
9 21 F apple OAS 5.56 n.d. RCA
10 29 M apple OAS 1.96 yes RCA
11 25 F salmon AX II <0.35 yes no
12 55 F apple OAS <0.35 yes RCA
13 41 M carrot OAS, AX I 6.16 yes A
14 28 F celery AX III 0.35 yes RCA
15a 46 F cape gooseberry OAS, AX II n.d. yes RCA, AE
15b peach OAS, AX II 3.89 yes
16 23 F soy drink OAS; AX III 0.48 yes RCA
17 34 F hazelnut OAS 3.37 n.d. RCA
18 35 F hazelnut OAS 13.7 n.d. RCA
19 60 F hazelnut OAS 0.82 yes A, RCA
20 64 F sesame OAS, AX II 12.7 yes RCA
21 22 F soy drink OAS, AX II 9.64 yes RCA, AE
22 63 F macadamia nut OAS, AX II <0.35 yes A, RCA
23a 59 F hazelnut AX I >100 yes A, RCA
23b almond AX I <0.35 yes
24 13 M kiwi AX I <0.35 yes A, RCA
25 21 M walnut AX IV 33.9 yes RCA
26 49 F hazelnut OAS 6.04 yes RCA
27 67 F kiwi OAS <0.35 yes no
28 55 F soy drink OAS, AX II 17.1 yes RCA, A
29 71 M kiwi OAS 0.47 yes RCA
30 36 F celery OAS 20.6 yes RCA
O nly those patients who developed oral symptoms upon mucosal food challenge are presented. F = Female; M = male; n.d. = not 
done; AE = atopic eczema; A = asthma; RCA = allergic rhinoconjunctivitis; AX = systemic anaphylactic reactions; I = mild reactions 
limited to the skin (e.g. angioedema, flush, and urticaria); II = moderate gastrointestinal, cardiovascular, and/or pulmonary symptoms 
(e.g. nausea, dyspnea, and dizziness); III = severe cardiovascular, and/or pulmonary symptoms (e.g. loss of consciousness, and asthma); 
IV = arrest.
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liva MCT increase was positive in 25 of 33 of the tests 
(75.8%) which had revealed oral symptoms during food 
exposure. None of the patients in whom oral reactions 
were absent during the challenge demonstrated an MCT 
increase in saliva at the 4-min measurement. The one pa-
tient who developed an exclusive systemic reaction after 
the challenge did not reveal an MCT increase in saliva 
either. 
 We also compared patients with a history of OAS to 
those who had had systemic allergic symptoms after food 
exposure. The percentage of patients who had a positive 
MCT increase after a positive clinical reaction upon food 
challenge was comparable (80.0% in 5 patients with a his-
tory of an exclusively systemic reaction and 72.0% in 25 
patients with a history of OAS; n.s.).
 Three selected patients in whom saliva MCT concen-
trations rose after the food challenge (No. 8, 17, and 18) 
underwent a placebo challenge with chewing gum. These 
patients neither developed symptoms nor showed chang-
es in the saliva MCT concentration. In 3 healthy subjects, 
no symptoms occurred when chewing carrot for 3 min. 
In these subjects, MCT in the saliva was not measurable 
before or after the mucosal challenge test.
Table 2.  Procedure and results of mucosal challenge tests (patients No. 3, 15, and 23 were tested twice with different foods)
Patient 
No.
Food challenge Amount of food
which caused
symptoms, g
Duration of mucosal
challenge until devel-
opment of symptoms 
Severity
of
symptoms
Baseline saliva
MCT concen-
tration, g/l
Saliva MCT concen-
tration 4 min after
start of symptoms, g/l
1 kiwi 6.2 120 moderate 0 7.31
2 almond 10.0 120 mild 1.45 9.06
3a hazelnut 5.5 40 moderate 0 56.6
3b almond 5.5 40 moderate 0 4.29
4 peach 10.7 60 mild 0 0
5 hazelnut 5.5 60 severe 0 0
6 carrot 6.0 100 moderate 1.42 6.16
7 soy drink 15.0 60 mild 0 0
8 carrot 70.0 270 mild 0 1.64
9 apple 48.3 120 moderate 0 2.51
10 apple 79.0 145 mild 0 1.5
11 salmon, uncooked 25 161 mild 2.61 15.8
12 apple 35.8 240 mild 0 2.66
13 carrot 41 160 severe 0 79.4
14 celery 15.2 140 severe 0 3.69
15a peach 74 510 moderate 0 3.03
15b cape gooseberry 16.1 340 mild 0 0
16 soy drink 10 90 moderate 0 8.74
17 hazelnut 7.7 120 severe 0 8.91
18 hazelnut 7.4 105 moderate 0 1.42
19 hazelnut 5.9 180 severe 0 0
20 sesame 0.02 100 mild 0 2.57
21 soy drink 40 240 mild 0 0
22 macadamia nuts 11.7 170 moderate 0 1.13
23a hazelnut 0.54 120 mild 0 2.99
23b almond 0.49 120 mild 0 2.8
24 kiwi 23.8 170 mild 0 0
25 walnut 0.36 120 moderate 0 0
26 hazelnut 3.0 135 moderate 0 18.8
27 kiwi 53 240 moderate 0 13.7
28 soy drink 20.0 150 mild 0 1.74
29 kiwi 44.6 180 moderate 0 5.47
30 celery 32.6 240 moderate 0 36.9
O nly those patients who developed oral symptoms upon mucosal food challenge are presented.
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 Discussion 
 In our institution, measurement of saliva MCT was 
incorporated into routine food challenge tests in 2006. 
Because the postchallenge kinetics of saliva MCT con-
centrations were largely unknown, we first tried to find 
out, using repeated measurements in patients with a high 
likelihood of oral symptoms, whether there was a pre-
ferred time point for a single posttest measurement. 
 In the majority of patients who had repeated measure-
ments during a 16-min postchallenge time, the maxi-
mum saliva MCT concentration occurred 4 min after the 
beginning of symptoms. Individual patients were tested 
with different foods and reacted in a similar way. In one 
patient who had initially had a delayed increase in MCT 
in saliva, we found that an artificially higher food dose 
increased the saliva MCT concentration already at 4 min. 
According to the results from placebo tests in patients 
and dummy tests in healthy controls, we can exclude an 
unspecific saliva MCT release by the act of mastication.
 During repeated measurements, the most striking ob-
servation was the rapid, but temporary increase in saliva 
MCT, which started to decline again after a few minutes. 
In the majority of patients, saliva MCT started to rise 
within 1 min after the appearance of the first subjective 
oral symptoms and returned to the pretest values after 16 
min or more. According to the results of repeated mea-
surements, however, it must be noted that there may be 
individual patients with a markedly delayed MCT re-
sponse. In those patients, an MCT increase would be 
missed by the 4-min measurement. 
 Further prospective studies will be required to pre-
cisely describe the time course of the saliva MCT concen-
tration after a challenge and to define optimal time points 
for sampling and the number of samples. It may be advis-
able to modify the challenge protocol in a way that the 
dose of test food is increased above the amount which has 
been indicated before by the patient to have resulted in 
symptoms. Increasing the number of early sampling 
points will be limited by restrictions concerning the sub-
lingual application time of the cotton roll. A time of less 
than 1 min will not be long enough to allow the cotton 
roll to absorb amounts of saliva, which are currently suf-
ficient for a precise MCT measurement.
 The postchallenge kinetics of MCT release into saliva 
appear to differ from what had been observed in other 
bodily fluids after allergen exposure. After a local aller-
gen challenge, a significant increase in MCT was demon-
strable in tear fluid only after 20 min  [9, 13] , and in nasal 
secretions only after 30 min  [7] . Although MCT has a 
half-life of several hours, it is measurable only during a 
short period of time because saliva is swallowed and be-
cause tears and nasal secretions are removed quickly. The 
rapid disappearance of MCT from saliva suggests that 
mucosal MCT release stops rapidly after the end of aller-
gen exposure. However, we cannot exclude the possibility 
that there might be a late phase reaction in single patients 
or a biphasic course of mucosal MCT release.
 Using the 4-min postchallenge sampling point, we sub-
sequently incorporated measurement of saliva MCT into 
routine mucosal challenge tests performed to diagnose pa-
tients with food allergy. A posttest increase in saliva MCT 
could be found in the vast majority of tests (79%), which 
was associated with oral symptoms upon food challenge. 
If a patient had not developed oral symptoms during the 
challenge (25% of the tests), there was no change in the sa-
liva MCT concentration. Moreover, the percentage of pos-
itive MCT responses did not depend on whether the tests 
had been performed in patients who had presented with a 
history of oral symptoms or in those with a history of ex-
clusively systemic symptoms. In the latter patients, we 
could avoid DBPCFC in 4 out of 5 cases by already obtain-
ing a positive test result after the mucosal challenge.
 The finding of a negative MCT increase in combina-
tion with a negative clinical result after the mucosal food 
challenge is difficult to interpret. Besides limitations due 
to the MCT saliva sampling point (see above), other ex-
planations are possible such as: (a) a change in the indi-
vidual pattern of immunological reactions by a variety of 
patient-specific mechanisms, (b) a change in food aller-
genicity for a variety of reasons (food generation, storage), 
and (c) an insufficient duration of oral food exposure. 
Therefore, the lack of a MCT release in the presence or 
absence of oral symptoms cannot be taken as a finding 
allowing the exclusion of a food allergy. On the other 
hand, a positive saliva MCT increase in combination with 
clinical symptoms should – when compared to the pres-
ence of subjective clinical symptoms alone – significant-
ly facilitate the diagnosis of a food allergy.
 Our results are seemingly in contradiction to results 
reported by Vila et al.  [11] . These authors reported an in-
creased saliva MCT concentration in only 1 out of 8 pa-
tients, all of whom had a systemic allergic reaction to a 
food challenge test. Their test design differed fundamen-
tally from that of our test in that the oral exposure time 
was not determined by the time which was known from 
the patient’s history to usually be required for the provo-
cation of oral symptoms. Patients were only asked to 
swallow the food after it had been chewed sufficiently, 
and there was no intention of making the patient keep the 
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food in his or her mouth beyond this point (until oral 
symptoms appeared). Another difference was that saliva 
MCT was only measured 5, 30, and 60 min after swallow-
ing the last test dose, and the collection time was not re-
lated to the onset of oral symptoms. 
 There are two mechanisms which possibly explain the 
negative results obtained by Vila et al.  [11] . According to 
our results, the time which had passed between oral ex-
posure and MCT measurement may have been too long 
to still allow the detection of MCT in saliva. Further-
more, there may be some type of mast cell exhaustion 
becoming evident after repeated exposure to the same 
type of food during a comparatively short time period. 
Finally, it should be noted that the molecular weight of 
MCT is of such a magnitude that the transport of MCT 
from serum into saliva is not possible; this principally 
prevents the detection of a primary systemic allergic reac-
tion via saliva examinations  [14] .
 Our study has several limitations mainly concerning 
the execution of the challenge test. The principal aim of 
our challenge procedure was to provoke clinical symp-
toms irrespective of the dose of food. Patients chewed the 
food to be examined until they developed symptoms or 
until that amount of time had passed, which was known 
from their history to usually be required for the provoca-
tion of symptoms. Because the provocation time varied 
from patient to patient and between different types of 
food (depending on consistency), the amount of food ac-
tually chewed during the test also varied significantly. 
Because the history of the patient was a central part of the 
individual planning and execution of the test, a certain 
subjective component remains. Nevertheless, even when 
considering those limitations, definitive conclusions can 
be made if positive MCT test results are obtained. The 
comparably high percentage of positive MCT results
in patients with oral symptoms during testing suggests 
that – in the context of our study design – measurement 
of allergen-induced saliva MCT may be a promising nov-
el diagnostic tool to confirm food allergy in patients with 
OAS and possibly also with anaphylaxis. In the latter pa-
tients, the need for a DBPCFC may even be eliminated. 
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